Alexandra Gerlach, Associate Editor

Luspatercept reduced the need for transfusion in patients with myelofibrosis (MF).

Patients with for HER2-positive breast cancer have an increased risk of developing brain tumors.

The humanized anti-butyrophilin 3A monoclonal antibody selectively activates Vγ9Vδ2 T-cells.

The approval is based on positive results from the phase 2/3 IND.227/KEYNOTE-483 trial.

The treatment significantly reduced risk of occurrence by 25% compared with endocrine therapy alone.

Ten-year follow up data showed a sustained survival benefit with nivolumab-ipilimumab in advanced melanoma.

Lebrikizumab (Ebglyss; Eli and Lilly Company) is a monthly maintenance injection with proven efficacy in adults and children aged 12 to 18 years.

Exposure to high cholesterol levels is a significant risk factor for atherosclerosis cardiovascular disease.

Researchers suggest prior treatments and follow-up duration may play a larger role.

Parents of children with cancer had the highest risk of developing mental illness and cardiovascular diseases.

Experts debate over the most effective treatment pathway for Richter transformation, highlighting the risks and benefits of different cellular therapies.

Treatment advancements highlight the curative potential of bone marrow transplants and emerging gene therapies.

The evolving treatment landscape for multiple myeloma includes debates on the timing and effectiveness of CAR T-cell therapy and quadruple immunotherapy regimens.

Optimizing outcomes for patients with chronic myeloid leukemia (CML) requires personalized treatment, adaptive dosing, and precise genetic insights.

New insights into heart failure risks in Native American communities are highlighting the need to address social determinants of health.

Pharmacists can enhance ASCVD management by supporting patient adherence through the administration and monitoring of inclisiran.

Mary McGann, PharmD, BCOP, offers insights into CAR T-cell therapy and the crucial role of pharmacists in mitigating resistance.

Pharmacists play a crucial role in supporting patients with HR+/HER2– breast cancer.

Accurate, effective screening is crucial for connecting patients with needed financial resources and support.

Patients can face barriers to BCMA-targeted treatments.

Pharmacists can be essential sources of education for patients, offering them guidance on safe use and proper dosage.

Palliative care is crucial for safe and effective medication management to relieve symptoms and improve quality of life.

Pharmacists are key resource points to navigate the nuances of keto diets and chronic health management.

The bispecific CAR T-cell therapy for treatment of multiple sclerosis is the first to target both CD19 and CD20.

Joseph Saseen offers valuable insights into the implications of the added performance and quality measures for patients and health care providers.

Propofol has a history of chronic shortage due to supply chain constraints.

The highly potent, selective URAT1 inhibitor may help reduce serum uric acid levels and treat clinically visible tophi.

The OTC antibody test can detect current or past infection but should be followed by additional testing to confirm diagnosis.

Craig Beavers discusses significance of the 2024 update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure.

CAR T-cell therapy in multiple myeloma faces challenges from the immunosuppressive cells in the tumor microenvironment.